Article

Phase II Activity of the HSP90 Inhibitor AUY922 in Patients with Alk-Rearranged (ALK+) or Egfr-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)

2012-09-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 50c9760f-f5ce-5f31-b596-681202a968fe
DOI: 10.1093/annonc/mds395

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase II Activity of the HSP90 Inhibitor AUY922 in Patients with Alk-Rearranged (ALK+) or Egfr-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)DOI 10.1093/annonc/mds395Read

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung CancerSemantic proximity Read

HSP90 inhibitors in lung cancer: promise still unfulfilled.Semantic proximity Read

HSP90: A promising target for NSCLC treatments.Semantic proximity Read

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.Semantic proximity Read

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studiesSemantic proximity Read

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.Semantic proximity Read

Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study DesignSemantic proximity Read

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.Semantic proximity Read

HSP90 and the cancer transcriptome: a comprehensive review of inhibitors and mechanistic insightsSemantic proximity Read

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)Semantic proximity Read

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).Semantic proximity Read

Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.Semantic proximity Read